[3H]Paroxetine binding in human platelets in relation to age and sex

Andersson, Anna; Marcusson, Jan

doi:10.1016/0197-4580(90)90026-v

Cited by 23 publications

(9 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is in agreement with previous reports (Andersson and Marcusson, 1990;Mellerup et al, 1993a,b;Maguire et al, 1993). Andersson and Marcusson (1 990) in particular, found no correlation in 47 normal subjects of age range 15-95 years.…”

Section: Discussionsupporting

confidence: 94%

“…In contrast, Klompenhouwer et al (1990) found that females had a higher BmaX and lower Kd than males in a study of 20 normal controls (1 IM, 9F). Other larger studies report no sex differences in [3H]-paroxetine binding parameters (Andersson and Marcusson, 1990;Mellerup etal., I993a,b). The difference between males and females arises from the control group as no sex differences were observed in the patient group.…”

Section: Discussionmentioning

confidence: 97%

See 1 more Smart Citation

Platelet [³H]‐paroxetine binding in obsessive‐compulsive disorder

Maguire

Norman

Apostolopoulos

et al. 1995

Human Psychopharmacology

View full text Add to dashboard Cite

Platelet [3H]‐paroxetine binding was analysed in 26 patients (13F, 13M) with obsessive compulsive disorder and 26 normal controls (13F, 13M). For patients with obsessive compulsive disorder, Bmax was 2127 ± 480 fmol/mg protein (mean±SD) compared to control Bmax values of 1926 ± 696 fmol/mg protein. The mean Kd value for the patients was 0.075 ± 0.025 nM and for the controls was 0.076 ± 0.032 nM. Analysis of covariance indicated a significant effect of sex on both Kd and Bmax but no effect of diagnosis (obsessive compulsive disorder versus normal controls) or season of sampling. The data provide no evidence for an abnormality of the platelet uptake mechanism as assessed by the measurement of [3H]‐paroxetine binding to the platelet transporter in obsessive compulsive disorder.

show abstract

Section: Discussionsupporting

confidence: 94%

Section: Discussionmentioning

confidence: 97%

Platelet [³H]‐paroxetine binding in obsessive‐compulsive disorder

Maguire

Norman

Apostolopoulos

et al. 1995

Human Psychopharmacology

View full text Add to dashboard Cite

show abstract

“…In another study of 35 subjects aged 19-97, B max but not K d for [ 3 H]imipramine binding decreased significantly with increasing age [7]. In contrast, no significant correlations between age and platelet [ 3 H]paroxetine binding were found in a study of 45 healthy subjects aged 15-95 [8] paroxetine has a twofold higher proportion of specific binding to the serotonin uptake site [11], indicating that it is a more appropriate radioligand than [ 3 H]imipramine for studies of the platelet serotonin transporter.…”

Section: Introductionmentioning

confidence: 91%

Binding of [3H]lysergic Acid Diethylamide to Serotonin 5-HT2A Receptors and of [3H]paroxetine to Serotonin Uptake Sites in Platelets from Healthy Children, Adolescents and Adults

Sigurdh

Spigset

Allard³

et al. 1999

Neuropsychobiology

View full text Add to dashboard Cite

Possible age effects on binding of [³H]lysergic acid diethylamide ([³H]LSD) to serotonin 5-HT_2A receptors and of [³H]paroxetine to serotonin uptake sites were studied in platelets from healthy children (11–12 years of age), adolescents (16–17 years of age) and adults. Significant overall age effects were found both for the number of binding sites (B_max) for [³H]LSD binding (p < 0.001), the affinity constant (K_d) for [³H]LSD binding (p < 0.001), B_max for [³H]paroxetine binding (p < 0.001) and K_d for [³H] paroxetine binding (p = 0.006). In general, there was a decrease in B_max with increasing age, which predominantly occurred between the ages 11–12 years and 16–17 years for the 5-HT_2A receptor, and after 16–17 years of age for the serotonin uptake site. These developmental changes might have an impact on the effect of treatment with serotonergic drugs in children and adolescents. When the platelet serotonin variables investigated are employed in studies in children or adolescents, age matching or, alternatively, introduction of age control in the statistical analysis should be performed.

show abstract

“…A decreased density of [ 3 H]imipramine-binding sites in elderly subjects has been reported by some authors [20,21], while others [28,29] have observed no age influence, albeit within a limited age range. While employing the [ 3 H]paroxetine binding, Andersson and Marcusson [22] did not detect any age-or sex-related effects in a group of subjects with, however, a wide range of ages. One study on the human brain [18] reported an apparent 'stability' of the [ 3 H]paroxetine binding in frontal cortex, but the mean age of the subjects included was relatively young (59 B 3 years) as compared with the traditional definition of elderly (165 years).…”

Section: Discussionmentioning

confidence: 99%

“…However, the findings derived from the evaluation of the 5-HT transporter have been controversial [20][21][22], due probably to the heterogeneity of the subjects used in the different studies.…”

Section: Introductionmentioning

confidence: 99%

Pharmacological Characterization of the Serotonin Transporter in Young and Elderly Subjects

Marazziti¹,

Baroni²,

Rossi³

et al. 2001

Neuropsychobiology

View full text Add to dashboard Cite

The potency of some tricyclics (imipramine and clomipramine) and selective 5-HT reuptake inhibitors (fluoxetine, paroxetine, and citalopram) in displacing the [³H]paroxetine binding to platelet membranes was measured in young and elderly subjects of both sexes. The results showed that the most potent compound in all subjects was paroxetine, followed by clomipramine, citalopram, fluoxetine, and imipramine, with no differences between male and female subjects. All drugs, except paroxetine and clomipramine, showed significantly lower pKi values in the elderly subjects of both sexes. These findings would suggest that although the pharmacological profile of the 5-HT transporter is not modified qualitatively by age, quantitative changes in its affinity do perhaps occur which would justify more careful studies on this topic in order to get optimal dosages of drugs acting at this level.

show abstract

[3H]Paroxetine binding in human platelets in relation to age and sex

Cited by 23 publications

References 22 publications

Platelet [³H]‐paroxetine binding in obsessive‐compulsive disorder

Platelet [³H]‐paroxetine binding in obsessive‐compulsive disorder

Binding of [<sup>3</sup>H]lysergic Acid Diethylamide to Serotonin 5-HT<sub>2A</sub> Receptors and of [<sup>3</sup>H]paroxetine to Serotonin Uptake Sites in Platelets from Healthy Children, Adolescents and Adults

Pharmacological Characterization of the Serotonin Transporter in Young and Elderly Subjects

Contact Info

Product

Resources

About

[3H]Paroxetine binding in human platelets in relation to age and sex

Cited by 23 publications

References 22 publications

Platelet [3H]‐paroxetine binding in obsessive‐compulsive disorder

Platelet [3H]‐paroxetine binding in obsessive‐compulsive disorder

Binding of [<sup>3</sup>H]lysergic Acid Diethylamide to Serotonin 5-HT<sub>2A</sub> Receptors and of [<sup>3</sup>H]paroxetine to Serotonin Uptake Sites in Platelets from Healthy Children, Adolescents and Adults

Pharmacological Characterization of the Serotonin Transporter in Young and Elderly Subjects

Contact Info

Product

Resources

About

Platelet [³H]‐paroxetine binding in obsessive‐compulsive disorder

Platelet [³H]‐paroxetine binding in obsessive‐compulsive disorder